P1/2, N=50, Active, not recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Mar 2027 | Trial primary completion date: Dec 2022 --> Mar 2022
over 1 year ago
Enrollment closed • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD19 expression • CD22 expression
|
cytarabine • cyclophosphamide • etoposide IV • fludarabine IV • Actemra IV (tocilizumab) • MB-CAR-T19-22